Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our top-notch dedicated system is used to design specialised libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q9Y6H6

UPID:
KCNE3_HUMAN

ALTERNATIVE NAMES:
MinK-related peptide 2; Minimum potassium ion channel-related peptide 2; Potassium channel subunit beta MiRP2

ALTERNATIVE UPACC:
Q9Y6H6

BACKGROUND:
The protein known as Potassium voltage-gated channel subfamily E member 3, or MinK-related peptide 2, is integral to the modulation of potassium ion flow in cardiac and skeletal tissues. By forming complexes with other potassium channel subunits, it influences the electrical activity of cells, crucial for muscle contraction and heart rhythm regulation.

THERAPEUTIC SIGNIFICANCE:
Linked to Brugada syndrome 6, a disorder that disrupts heart rhythm, the study of Potassium voltage-gated channel subfamily E member 3 offers promising avenues for therapeutic intervention. Its pivotal role in heart function underscores the potential for targeted treatments that could mitigate or prevent the life-threatening episodes associated with this syndrome.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.